Patent Filed by Sosei Group Corp for Novel Compounds Treating Apelin Receptor Disorders

According to GlobalData’s company profile on Sosei Group, was a key innovation area identified from patents. Sosei Group‘s grant share as of January 2024 was 31%. Grant share is based on the ratio of number of grants to total number of patents.

The patent application (Publication Number: US20230382950A1) discloses a compound with a specific chemical sequence as defined in claim 1. The compound includes various components such as Q, n, R1, R2, X, AA1, AA2, AA3, AA5, and AA8, each playing a crucial role in the compound’s structure and function. Additionally, the compound exhibits apelin receptor agonist activity, making it potentially useful in the treatment of various conditions related to cardiovascular disease, heart failure, diabetes, cancer, HIV infection, and other medical conditions.

Furthermore, the patent application also covers the pharmaceutical composition containing the compound along with a pharmaceutically acceptable excipient for use in medicine. The compound and composition are specifically indicated for treating a wide range of conditions such as cardiovascular disease, diabetes, hypertension, kidney failure, thrombotic diseases, and metabolic conditions. The compound’s unique structure and properties make it a promising candidate for therapeutic interventions targeting these complex medical conditions. The patent application provides detailed information on the compound’s composition, potential applications, and its role in addressing various health issues, highlighting its significance in the field of medicine and pharmaceuticals.

To know more about GlobalData’s detailed insights on Sosei Group, buy the report here.

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

G lobalDat a, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies

Xencor Inc Files Patent for Bispecific Antibody to Treat GPC3-Associated Cancers

Share this article According to GlobalData’s company profile on Xencor, Personalized cancer vaccines was a key innovation area identified from patents. Xencor‘s grant share as

April 4, 2024

Neuroscience has to grapple with a long legacy of racism if it wants to move into the future

Many parts of neuroscience research have a race problem. Black people are often excluded from studies due to the texture of their hair, receive erroneous

November 29, 2023

A novel approach to biomolecule engineering

Thanks to a serendipitous discovery and a lot of painstaking work, scientists can now build biohybrid molecules that combine the homing powers of DNA with

September 18, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.